Form 4: RA Capital Exchanges 535,000 Shares of 4D Molecular Therapeutics for Pre-Funded Warrants

RA Capital Healthcare Fund exchanged 535,000 shares of 4D Molecular Therapeutics common stock for pre-funded warrants exercisable for the same number of shares at a nominal price.

Summary

• RA Capital Healthcare Fund, L.P. exchanged 535,000 shares of 4D Molecular Therapeutics common stock for pre-funded warrants.
• The warrants are exercisable for up to 535,000 shares of common stock at an exercise price of $0.0001 per share.
• The exchange was made with no additional consideration.
• The pre-funded warrants have no expiration date and are exercisable immediately.
• The reporting persons cannot exercise the warrants if it would cause their ownership to exceed 9.99% of the total outstanding shares.

Sentiment

Score: 7

Explanation: The document reflects a standard financial transaction with no significant positive or negative implications. The exchange provides flexibility for RA Capital and is a common practice in the biotech industry.

Positives

• The pre-funded warrants provide RA Capital with the option to increase their stake in 4D Molecular Therapeutics at a very low cost.
• The warrants are immediately exercisable and have no expiration date, providing flexibility.

Risks

• The exercise of the warrants is capped at 9.99% ownership, limiting RA Capital's potential upside.
• The nominal exercise price of $0.0001 per share could be seen as a dilution risk for existing shareholders if exercised.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• Peter Kolchinsky, Manager of RA Capital Management, L.P., signed the filing.
• Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, signed the filing.
• Peter Kolchinsky signed the filing individually.
• Rajeev Shah signed the filing individually.

Industry Context

This transaction is a specific financial maneuver by a major healthcare fund and does not necessarily reflect broader industry trends, but it does show continued investment in biotech companies.

Comparison to Industry Standards

• Pre-funded warrants are a relatively common financial instrument used in the biotech industry, particularly for companies with significant research and development costs.
• The nominal exercise price of $0.0001 is typical for pre-funded warrants, which are often used to provide immediate capital while deferring the issuance of new shares.
• The 9.99% ownership cap is a standard provision to avoid triggering certain regulatory requirements and to maintain flexibility for the investor.

Stakeholder Impact

• The exchange of shares for pre-funded warrants could have a minor dilutive effect on existing shareholders if the warrants are exercised.
• The transaction provides RA Capital with increased flexibility in their investment in 4D Molecular Therapeutics.

Key Dates

Keywords

pre-funded warrants, RA Capital, 4D Molecular Therapeutics, share exchange, common stock, investment, healthcare fund